Document is current
Any future updates will be listed below
-
Authors
Filippi, Massimo https://orcid.org/0000-0002-5485-0479
Cecchetti, Giordano https://orcid.org/0000-0002-6544-410X
Cagnin, Annachiara https://orcid.org/0000-0002-2894-0825
Marra, Camillo https://orcid.org/0000-0003-3994-4044
Nobili, Flavio https://orcid.org/0000-0001-9811-0897
Parnetti, Lucilla https://orcid.org/0000-0001-5722-3967
Agosta, Federica https://orcid.org/0000-0003-3121-4979
-
Funding
Funding for this research was provided by:
Biogen
- License Information
-
More Information
Article History
Received: 12 January 2023
Revised: 20 February 2023
Accepted: 20 February 2023
First Online: 9 March 2023
Declarations
:
: M. Filippi is Editor-in-Chief of the Journal of Neurology and Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services and/or speaking activities from Almiral, Alexion, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries, and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). G. Cecchetti has received speaker honoraria from Neopharmed Gentili. C. Marra is Associate Editor of Journal of Alzheimer’s disease, received compensation for consulting services and/or speaking activities from Biogen, Roche, Novo-Nordisk, Angelini, PIAM, and receives research support from Biogen Idec, Novo Nordisk, EISAI, and AIFA. A. Cagnin received compensation for consulting services and/or speaking activities from Biogen, Roche, Angelini, and PIAM and receives research support from Italian Ministry of Health. F. Nobili has received honoraria for advisory board participation by Roche and Biogen, for consultation from BIAL, and speaker honoraria from G.E. healthcare. L. Parnetti is the Vice President of the Society for CSF Analysis and Clinical Neurochemistry; Director of the Fresco Perugia Excellence Centre for Parkinson’s Disease; and receives research support from the European Joint Programme on Neurodegenerative Diseases (JPND, European Union’s Horizon 2020 research and innovation programme), Marie-Curie Actions, Horizon 2020, Airalzh-Grants-for-Young-Researchers—AGYR2020 (AirAlzh), Fresco Parkinson Institute, the US Parkinson’s Foundation, and the Italian Ministry of Health–PNRR. F. Agosta is Associate Editor of NeuroImage: Clinical, has received speaker honoraria from Roche, Biogen Idec, Zambon and Italfarmaco, and receives or has received research supports from the Italian Ministry of Health, AriSLA (Fondazione Italiana di Ricerca per la SLA), and the European Research Council and Foundation Research on Alzheimer Disease.
: An ethical standard statement is not required. This study did not involve human participants, their data or biological material. This is an axpert opinion and practical guideline.
